Nguyen Mary M, Gianneschi Nathan C, Christman Karen L
Department of Bioengineering and Sanford Consortium for Regenerative Medicine, University of California, San Diego, United States.
Department of Chemistry and Biochemistry, University of California, San Diego, United States.
Curr Opin Biotechnol. 2015 Aug;34:225-31. doi: 10.1016/j.copbio.2015.03.016. Epub 2015 Apr 11.
Injectable nanomaterials have been designed for the treatment of myocardial infarction, particularly during the acute stages of inflammation and injury. Among these strategies, injectable nanofibrous hydrogel networks or nanoparticle complexes may be delivered alone or with a therapeutic to improve heart function. Intramyocardial delivery of these materials localizes treatments to the site of injury. As an alternative, nanoparticles may be delivered intravenously, which provides the ultimate minimally invasive approach. These systems take advantage of the leaky vasculature after myocardial infarction, and may be designed to specifically target the injured region. The translational applicability of both intramyocardial and intravenous applications may provide safe and effective solutions upon optimizing the timing of the treatments and biodistribution.
可注射纳米材料已被设计用于治疗心肌梗死，特别是在炎症和损伤的急性期。在这些策略中，可注射的纳米纤维水凝胶网络或纳米颗粒复合物可以单独给药或与治疗剂一起给药，以改善心脏功能。这些材料的心肌内递送将治疗定位到损伤部位。作为一种替代方法，纳米颗粒可以静脉内给药，这提供了最终的微创方法。这些系统利用了心肌梗死后血管渗漏的特点，并且可以设计成特异性靶向损伤区域。心肌内和静脉内应用的转化适用性在优化治疗时机和生物分布后可能提供安全有效的解决方案。
